References were identified in PubMed using the search terms “experimental infection”, “human challenge”, “challenge study”, “challenge model”, “human infection”, “infection model”, “volunteer study”, “infection in volunteers”, “volunteer challenge”, and “controlled human infection” separately combined with each pathogen listed in the table. For each pathogen, the Mesh-term was combined with an [All Fields] search of common synonyms. We searched for articles published between Jan 1, 1900 and Oct
ReviewExperimental infection of human volunteers
Introduction
Controlled human infections (CHIs), through the transfer of body fluid such as serum,1 respiratory secretions,2 or faecal filtrates,3 laid the foundation for infectious disease research in the 17th century. Unparalleled human experimentation led to the identification of causative organisms (norovirus,3 influenza,2 dengue,4 and sarcocystis5), not only proving Koch's postulates, but also providing an opportunity to study incubation periods and clinical disease. Important discoveries were made such as the identification of toxins that caused diarrhoeal disease following instillation of Vibrio cholerae culture broth in volunteers in 1966.6 Although the ethics of these initial studies were often questionable, the realisation that they provided a core platform for the study of infections has resulted in the increased use of CHI models in the past decades. Ethical frameworks have been developed and rigorous independent review boards assess risks and benefits. CHI studies are moving from investigations that have exploratory and descriptive aims to trials that take a central position in the development pipeline of vaccines and drugs.7 CHI trials often act as a gatekeeper before proceeding to field efficacy trials, although in exceptional cases, can be accepted as proof of efficacy in phase 3 clinical development.8 Each CHI model has been designed with specific inocula, endpoints, or clinical procedures as a fit-for-purpose model (table). The development of novel CHI models and the exploitation of existing CHI models in the product development pipeline have been endorsed by large funders such as the Bill & Melinda Gates Foundation, the Wellcome Trust, and the UK Medical Research Council, who have dedicated funds to CHI models. CHI studies, by allowing preliminary efficacy testing in 10–100 participants, are cheaper than phase 2 and 3 clinical trials in endemic areas that often require sample sizes ranging from hundreds to 100 000 participants. Additionally, CHI studies allow for testing of many products, minimise the risk of late clinical failure, and reduce unnecessary exposure of potentially vulnerable populations to interventions (figure 1).
In CHI trials biomarkers, protective responses, and mechanisms of disease can be studied, which ultimately feed back into the product development pipeline to improve the next generation of medicines. Novel technological advances such as omics tools are used to identify risk factors including diet, microbiome, co-infections, or genetic background using complex multiparametric analyses. Pathogens are altered by genetic modification to identify key virulence genes (eg, NCT03067961) or to provide less virulent challenge inocula that can decrease the clinical severity of CHI models.36 In this Review, we provide an overview of the active CHI models, discuss their contribution to biomedical science, and suggest some predictions of what can be expected in this dynamic field in the future.
Section snippets
Ethical considerations
The son of Edward Jenner's gardener has become the historic symbol of CHI when he was inoculated with cowpox in 1796. Other infamous examples are infection of the MacDonalds' children with pertussis, infection of children with intellectual disability at Willowbrook State school in New York with hepatitis virus,37 and malaria infections in Nazi Germany.38 The Nuremberg Code (1946) and the Declaration of Helsinki (1964) now provide guidelines for the conduct of medical research involving human
CHI in product development
The contribution of CHI studies to the development of novel vaccines is shown by the Live Oral Cholera Vaccine CVD 103-HgR study in 197 healthy volunteers.8 CVD 103-HgR was licensed in several countries since 1993, but only recently in the USA.53 Volunteers were challenged by ingestion of wild-type V cholerae and were monitored for the occurrence of moderate or severe diarrhoea. The vaccine showed 90% efficacy, which, together with a good safety profile, led to licensure by the Food and Drug
Novel CHI models in poverty-related and neglected diseases
Because of the potential to reduce costs and time to registration, CHI models are particularly appealing for the development of products for resource-poor countries where infectious diseases are still responsible for considerable morbidity and mortality. Aside from malaria, Mycobacterium tuberculosis is an obvious infection that falls into this category. An M tuberculosis CHI model could provide a crucial platform for the selection of potential novel antibiotics and vaccine candidates. CHI
Colonisation models
Culture-independent technologies have revealed the diversity of the human microbiome.113 In an era of increasing antimicrobial resistance, the study of controlled colonisation in healthy volunteers has proven to be instrumental to dissect the dynamics of mucosal carriage of bacteria that precedes invasive bacterial infection. With regards to controlled colonisation, the upper respiratory tract microbiome has been the most studied.
The most frequently used model for colonisation is nasal
Scientific advances
CHI trials offer unprecedented opportunities to study host–pathogen interaction by taking multiple longitudinal samples before, during, and after infection. Profiling immune parameters and linking them to the clinical outcome is extremely valuable for identifying correlates of protection. The availability of validated correlates of protection will accelerate the development of novel vaccines by providing a surrogate endpoint for phase 2 field trials. Additionally, such insight could guide the
Future challenges and opportunities
The increasing costs for clinical development of novel drugs and vaccines for infectious diseases calls for tools to select candidates with highest probability of success. The concept of fast failure in which the development of unsuccessful candidates is stopped early is extremely important as it allows the reallocation of resources. CHI studies could be used as models for phase 2 clinical efficacy and so could reduce development risk, reduce overall costs, and increase risk-adjusted net
Search strategy and selection criteria
References (143)
- et al.
Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies
Int J Infect Dis
(2016) - et al.
Dengue human infection models to advance dengue vaccine development
Vaccine
(2015) - et al.
Design, recruitment, and microbiological considerations in human challenge studies
Lancet Infect Dis
(2015) - et al.
Utility of animal and in vivo experimental infection of humans with rhinoviruses in the development of therapeutic agents for viral exacerbations of asthma and chronic obstructive pulmonary disease
Pulm Pharmacol Ther
(2015) - et al.
A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC)
Vaccine
(2011) - et al.
Controlled human infection with RSV: The opportunities of experimental challenge
Vaccine
(2017) - et al.
Use of lactobacillus probiotics for bacterial genitourinary infections in women: a review
Clinical Ther
(2008) - et al.
Plasmodium vivax controlled human malaria infection—progress and prospects
Trends Parasitol
(2017) - et al.
Evaluation of dengue virus strains for human challenge studies
Vaccine
(2014) - et al.
The victims of unethical human experiments and coerced research under National Socialism
Endeavour
(2016)
Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma
Chest
Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR
Travel Med Infect Dis
Development of the RTS,S/AS malaria candidate vaccine
Vaccine
The production of mature gametocytes of Plasmodium falciparum in continuous cultures of different isolates infective to mosquitoes
Trans R Soc Trop Med Hyg
Paludrine treatment of experimental malaria infection; effective minimum doses
Trans R Soc Trop Med Hyg
DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection
Lancet Infect Dis
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
Lancet Infect Dis
Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection
Lancet
DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial
Vaccine
Comparative therapeutic effect of aerosolized and oral rimantadine HCl in experimental human influenza A virus infection
Antiviral Res
Status of vaccine research and development for norovirus
Vaccine
Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers
Gastroenterology
Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes
FEMS Microbiol Immunol
Research on dengue during World War II
Am J Trop Med Hyg
Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates
J Infect Dis
Observation on the clinical symptoms and sporocyst excretion in human volunteers experimentally infected with Sarcocystis hominis
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi
Experimental cholera in humans
BMJ
Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor
Clin Infect Dis
NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections
J Infect Dis
Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites
Am J Trop Med Hyg
The utility of human challenge studies in vaccine development: lessons learned from cholera
Vaccine (Auckl)
An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution
Clin Infect Dis
The shigella human challenge model
Epidemiol Infect
Norovirus vaccine against experimental human Norwalk virus illness
N Engl J Med
Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans
J Infect Dis
Experimental human pneumococcal carriage
J Vis Exp
Immunopathogenesis of Haemophilus ducreyi infection (chancroid)
Infect Immun
From rabbits to humans: the contributions of Dr Theodore E Woodward to tularemia research
Clin Infect Dis
Nasal inoculation of the commensal Neisseria lactamica inhibits carriage of Neisseria meningitidis by young adults: a controlled human infection study
Clin Infect Dis
Campylobacter jejuni strain CG8421: a refined model for the study of campylobacteriosis and evaluation of campylobacter vaccines in human subjects
Clin Infect Dis
Cryptosporidium hominis: experimental challenge of healthy adults
Am J Trop Med Hyg
The infectivity of Cryptosporidium parvum in healthy volunteers
N Engl J Med
Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study
Clin Exp Allergy
Bacterial interference for prevention of urinary tract infection
Clin Infect Dis
A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guérin
J Infect Dis
Experimental gonococcal infection in male volunteers: cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC
Front Microbiol
Antigenic variation of Giardia lamblia in experimental human infections
J Immunol
Challenge model for Helicobacter pylori infection in human volunteers
Gut
Evaluation of the clinical and microbiological response to Salmonella paratyphi A infection in the first paratyphoid human challenge model
Clin Infect Dis
Experimental parvoviral infection in humans
J Infect Dis
Cited by (102)
Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy
2023, The Lancet Infectious DiseasesViral infection and allergy status impact severity of asthma symptoms in children with asthma exacerbations
2022, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :Other viruses have also been implicated in exacerbations of asthma, including respiratory syncytial virus (RSV), coronaviruses, human metapneumovirus, human parainfluenza viruses, and enteroviruses.4-6 In an effort to understand mechanisms of virus-related asthma exacerbations (VRAEs), subjects with controlled asthma have undergone experimental inoculation with RV.7-10 Although this approach has provided information regarding immune responses and symptoms during VRAE, it has become clear that more research is needed in those with uncontrolled asthma, as clinical outcomes are often worse within this population.
Remodelling selection to optimise disease forecasts and policies
2024, Journal of Physics A: Mathematical and Theoretical